The Spine Institute uses an Adult Stem Cell Therapy that doesn’t require FDA approval to treat lumbar and cervical spine conditions resulting from injury or aging, and is also involved with an FDA clinical trial investigating the use of Adult Stem Cells.
The Spine Institute, in partnership with the Orthopedic Stem Cell Institute and SpineSmith®/Celling Technologies, uses mesenchymal adult stem cells that function to repair and replace damaged tissue. These stem cells are autologous – they are taken from an adult patient and returned to that same patient in a concentrated form to the damaged area in a 30-minute procedure. This type of adult stem cell therapy does not require FDA approval to administer.
For more information on Adult Stem Cell Therapy and the Orthopedic Stem Cell Institute, visit www.OrthopedicStemCellInstitute.com.
Mesoblast, a leader in adult stem cell product research, has developed a process to immunoselect the mesenchymal precursor cells (stem cells) from adult bone marrow mononuclear cells and then expand these stem cells in culture to produce allogenic MPCs (NeoFuse™). These expanded stem cells have been shown to retain the mesenchymal cell capacity for differentiation into bone, cartilage, and adipose tissue in-vitro and to regenerate bone in-vivo.
If you are interested in participating in a stem cell research study, please contact our research coordinator.
21 Spine Surgeons Researching Stem Cell Treatments (Dr. Pettine is included.)